Vmbook Online ordering
Ignyta Inc
As an AI model, I don't have access to real-time market data. However, I can provide you with general information about RXDX, a publicly traded biotech company listed on the US stock exchange.
RXDX, also known as Reata Pharmaceuticals, is a biotechnology company that focuses on identifying, developing, and commercializing product candidates that can significantly improve treatment options for patients with serious diseases. The company's mission is to address significant unmet needs in medicine, particularly in the areas of filtration and inflammation.
In terms of earnings, the company's fiscal year ends in December, and their financial statements are available publicly. In their most recent quarterly report, RXDX reported a net loss of $43.4 million, or $0.84 per share, compared to a net loss of $23.7 million, or $0.52 per share, for the same period in the previous year. The company had $242.2 million in cash and investments as of March 31, 2022.
Regarding growth, RXDX has been expanding its pipeline and advancing its product candidates through various clinical trials. The company's most advanced product candidate is bardoxolone methyl (formerly known as RX-0201), which is an oral activator of Nrf2, a transcription factor that promotes the expression of genes involved in mitochondrial function and antioxidant defense. Bardoxolone methyl is being studied in several diseases, including pulmonary arterial hypertension, chronic kidney disease, and idiopathic pulmonary fibrosis. Additionally, RXDX is developing a second product candidate, RX-0147, which is an oral porcupine inhibitor that is being developed for the potential treatment of cancer.
Overall, RXDX is a biotech company that focuses on developing innovative therapies in areas with significant unmet medical needs. While their financials show a net loss in their recent quarterly report, the company has a promising pipeline of product candidates in various stages of clinical trials, which could potentially drive future growth.
Please keep in mind that this information is not real-time and may have changed since my knowledge cutoff. Additionally, it's essential to thoroughly research and consult financial reports, analyst estimates, and market data from reliable sources before making investment decisions.